View more in
Cancer

Patients With Stage III NSCLC Continue to Derive Benefit From Durvalumab After Chemoradiation

cancernetwork.com
 2021-06-04

Cover picture for the articleData presented at the 2021 ASCO Annual Meeting from the phase 3 PACIFIC trial show long-term survival benefit for patients with unresectable stage III non–small cell lung cancer treated with durvalumab following chemoradiotherapy. Superior survival end points were reported with durvalumab (Imfinzi) versus placebo as treatment of patients with stage...

www.cancernetwork.com

Comments / 0

Comments / 0